NASDAQ:AMEDAmedisys Stock Price, Forecast & News

Amedisys' stock was trading at $170.47 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMED stock has increased by 21.9% and is now trading at $207.77. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amedisys in the last year. There are currently 4 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amedisys.

Amedisys is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Amedisys.

Amedisys Inc (NASDAQ:AMED) issued its quarterly earnings results on Wednesday, May, 6th. The health services provider reported $1.05 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.97 by $0.08. The health services provider had revenue of $491.70 million for the quarter, compared to analysts' expectations of $507.45 million. Amedisys had a return on equity of 23.09% and a net margin of 6.43%. The company's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same quarter last year, the company posted $1.11 earnings per share. View Amedisys' earnings history.

13 Wall Street analysts have issued twelve-month target prices for Amedisys' stock. Their forecasts range from $125.00 to $260.00. On average, they anticipate Amedisys' share price to reach $196.15 in the next twelve months. This suggests that the stock has a possible downside of 5.6%. View analysts' price targets for Amedisys.

News coverage about AMED stock has been trending very negative recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Amedisys earned a news sentiment score of -3.8 on InfoTrie's scale. They also gave news articles about the health services provider a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View the latest news about Amedisys.

Amedisys saw a decline in short interest in June. As of June 30th, there was short interest totaling 1,070,000 shares, a decline of 10.8% from the June 15th total of 1,200,000 shares. Based on an average daily trading volume, of 326,500 shares, the days-to-cover ratio is presently 3.3 days. Approximately 3.4% of the shares of the company are sold short. View Amedisys' Current Options Chain.

Some companies that are related to Amedisys include Laboratory Corp. of America (LH), Quest Diagnostics (DGX), Davita (DVA), Chemed (CHE), LHC Group (LHCG), AMN Healthcare Services (AMN), MEDNAX (MD), R1 RCM (RCM), CorVel (CRVL), The Providence Service (PRSC), Tivity Health (TVTY), Cross Country Healthcare (CCRN) and Interpace Diagnostics Group (IDXG). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amedisys investors own include Alibaba Group (BABA), NVIDIA (NVDA), Adobe (ADBE), Cisco Systems (CSCO), Netflix (NFLX), CVS Health (CVS), Intel (INTC), Micron Technology (MU), Pfizer (PFE) and Vertex Pharmaceuticals (VRTX).

Amedisys trades on the NASDAQ under the ticker symbol "AMED."

Amedisys' stock is owned by a variety of retail and institutional investors. Top institutional investors include Riverbridge Partners LLC (2.08%), Envestnet Asset Management Inc. (0.13%), Gradient Investments LLC (0.07%), Polianta Ltd (0.02%), HBW Advisory Services LLC (0.01%) and Contravisory Investment Management Inc. (0.00%). Company insiders that own Amedisys stock include Bruce D Perkins, Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Linda J Hall, Michael Paul North, Scott G Ginn, Sharon Brunecz, Teresa L Kline and Vickie L Capps. View institutional ownership trends for Amedisys.

AMED stock was sold by a variety of institutional investors in the last quarter, including Gradient Investments LLC. Company insiders that have sold Amedisys company stock in the last year include Christopher Gerard, David B Pearce, David L Kemmerly, Donald A Washburn, Jake L Netterville, Jeffrey A Rideout, Julie D Klapstein, Michael Paul North, Scott G Ginn, and Sharon Brunecz. View insider buying and selling activity for Amedisys.

AMED stock was bought by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Polianta Ltd, Envestnet Asset Management Inc., HBW Advisory Services LLC, and Contravisory Investment Management Inc.. Company insiders that have bought Amedisys stock in the last two years include Bruce D Perkins, Teresa L Kline, and Vickie L Capps. View insider buying and selling activity for Amedisys.

Shares of AMED can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMED stock can currently be purchased for approximately $207.77.

Amedisys has a market capitalization of $6.73 billion and generates $1.96 billion in revenue each year. The health services provider earns $126.83 million in net income (profit) each year or $4.40 on an earnings per share basis. Amedisys employs 21,300 workers across the globe.

The official website for Amedisys is www.amedisys.com.

Amedisys' mailing address is 3854 AMERICAN WAY SUITE A, BATON ROUGE LA, 70816. The health services provider can be reached via phone at 225-292-2031 or via email at [email protected]